

Catalog # BP6587a

**COL6A1 Antibody (N-term) Blocking Peptide** Synthetic peptide

Specification

## **COL6A1 Antibody (N-term) Blocking Peptide - Product Information**

Primary Accession

<u>P12109</u>

#### COL6A1 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 1291

**Other Names** Collagen alpha-1(VI) chain, COL6A1

Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/products/AP6587a>AP6587a</a> was selected from the N-term region of human COL6A1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

#### **COL6A1** Antibody (N-term) Blocking Peptide - Protein Information

Name COL6A1

**Function** Collagen VI acts as a cell-binding protein.

**Cellular Location** Secreted, extracellular space, extracellular matrix

#### **COL6A1 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides



# COL6A1 Antibody (N-term) Blocking Peptide - Images

## COL6A1 Antibody (N-term) Blocking Peptide - Background

The collagens are a superfamily of proteins that play a role in maintaining the integrity of various tissues. Collagens are extracellular matrix proteins and have a triple-helical domain as their common structural element. Collagen VI is a major structural component of microfibrils. The basic structural unit of collagen VI is a heterotrimer of the alpha1(VI), alpha2(VI), and alpha3(VI) chains. The protein COL6A1 is the alpha 1 subunit of type VI collagen (alpha1(VI) chain). Mutations in the genes that code for the collagen VI subunits result in the autosomal dominant disorder, Bethlem myopathy.

#### **COL6A1 Antibody (N-term) Blocking Peptide - References**

Martoni, E., Hum. Mutat. 30 (5), E662-E672 (2009)Kim, T.H., J. Rheumatol. 35 (9), 1849-1852 (2008)Fujita, A., Genet. Mol. Res. 7 (2), 371-378 (2008)